Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients With Testicular Cancer

Bokemeyer, B.; Berger, C; Hartmann, Jakob; Kollmannsberger, C.; Schmoll, Hans‐Joachim; Kuczyk, Markus A.; Kanz, Lothar

doi:10.1016/s0022-5347(01)62317-6

Cited by 17 publications

(22 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may be related to dose, age of the patient, and other factors, such as noise exposure (Bokemeyer et al 1998), exposure to other ototoxic drugs, depleted nutritional state, including low serum albumin and anemia (Kopelman et al 1988), and cranial irradiation (Huang et al 2002). Young children seem to be more susceptible than adults (Li et al 2004).…”

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

“…Young children seem to be more susceptible than adults (Li et al 2004). Hearing loss often is permanent and bilaterally symmetric (Bokemeyer et al 1998). Symptoms of ototoxicity include subjective hearing loss, ear pain, or tinnitus (Reddel et al 1982).…”

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

“…If ultra-high-frequency audiometric testing is used, up to 100% of patients receiving high-dose cisplatin (150–225 mg/m 2 ) may show some degree of hearing loss (Kopelman et al 1988). Dose-related ototoxicity is illustrated by the report that 20% of patients treated with cisplatin for testicular cancer experience permanent ototoxicity, but > 50% of patients who received cisplatin in doses > 400 mg/m 2 cumulative dose had permanent hearing loss (Bokemeyer et al 1998). A good correlation between transient otoacoustic emissions and pure tone audiometric thresholds was shown in children.…”

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

See 2 more Smart Citations

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

Rybak

Mukherjea

Jajoo

et al. 2009

Tohoku J. Exp. Med.

327

246

View full text Add to dashboard Cite

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

Section: Clinical Ototoxicity Of Cisplatinmentioning

confidence: 99%

See 1 more Smart Citation

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

Rybak

Mukherjea

Jajoo

et al. 2009

Tohoku J. Exp. Med.

327

246

View full text Add to dashboard Cite

“…However, it presents severe side effects such as nephrotoxicity, bone marrow toxicity, gastrointestinal toxicity, liver toxicity, peripheral nervous system toxicity and ototoxicity [21]. Most of these related effects can be treated.…”

Section: Introductionmentioning

confidence: 99%

Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment

et al. 2016

View full text Add to dashboard Cite

We provide evidence for the presence of cannabinoid CB2 receptors in some cellular types of the cochlea of the adult albino rat. Cannabinoids and their receptors are increasingly being studied because of their high potential for clinical use. As a hyperspecialized portion of the peripheral nervous system, study of the expression and function of cannabinoid receptors in the hearing organ is of high interest. Stria vascularis and inner hair cells express CB2 receptor, as well as neurites and cell bodies of the spiral ganglion. Cellular types such as supporting cells and outer hair cells, in which the expression of other types of functional receptors has been reported, do not significantly express CB2 receptors in this study. An up-regulation of CB2 gene expression was detected after an ototoxic event such as cisplatin treatment, probably due to pro-inflammatory events triggered by the drug. That fact suggests promising potential of CB2 receptor as a therapeutic target for new treatments to palliate cisplatin-induced hearing loss and other ototoxic events which triggers inflammatory pathways.

show abstract

“…It is more pronounced when cisplatin is given once every 2 weeks and when cisplatin dosages are more than 60 mg/m. 2,21 Investigations using audiometric techniques show a frequency of cisplatin-induced ototoxicity of approximately 20% to 40% after a high cumulative dose of cisplatin 22 of 400 mg/m 2 ; therefore, a certain level of ototoxicity is expected with the EP-EMA regimen. At present, the only way to prevent cisplatin-induced ototoxicity is a limitation of the dose per cycle, the cumulative dose, and the dose intensity.…”

Section: Discussionmentioning

confidence: 99%

EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia

Han

Amant

Leunen

et al. 2012

International Journal of Gynecological Cancer

View full text Add to dashboard Cite

Eighteen patients were treated with EP-EMA, either as first-line chemotherapy for high-risk gestational trophoblastic neoplasia (n = 6), placental site trophoblastic tumor (n = 1), or as salvage chemotherapy for gestational trophoblastic neoplasia after single-agent methotrexate (methotrexate, 1 mg/kg, on days 1, 3, 5, and 7 every two weeks) (n = 10) or high-dose methotrexate-etoposide: methotrexate, 1000 mg/m, on day 1; etoposide, 100 mg/m, on days 1 to 2, every week) (n = 1). Median number of cycles of EP-EMA was 8 (range, 3-11). Median follow-up was 19 months (range, 7-77 months). Concerning response rate, 16 patients (89%) achieved complete remission without disease recurrence.Two patients (11%) died: One patient with placental site trophoblastic tumor died of progressive disease; the second patient presented with choriocarcinoma, primarily metastasized to liver, lung, skin, kidney, and brain. She died of sepsis and endocarditis after adding intrathecal methotrexate and switching cisplatin to carboplatin in the EP-EMA regimen. Toxicity was significant. Eight treatment changes were made owing to grade 2 to grade 3 ototoxicity: 7 to high-dose methotrexate-etoposide, 1 change of cisplatin to carboplatin. Fifteen patients (83%) experienced grade 3/4 neutropenia.

show abstract

Analysis of Risk Factors for Cisplatin-Induced Ototoxicity in Patients With Testicular Cancer

Cited by 17 publications

References 0 publications

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

Cisplatin Ototoxicity and Protection: Clinical and Experimental Studies

Spontaneous Cannabinoid Receptor 2 (CB2) Expression in the Cochlea of Adult Albino Rat and Its Up-Regulation after Cisplatin Treatment

EP-EMA Regimen (Etoposide and Cisplatin With Etoposide, Methotrexate, and Dactinomycin) in a Series of 18 Women With Gestational Trophoblastic Neoplasia

Contact Info

Product

Resources

About